Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

191 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Successes and lessons learned in database development for national multi-site cancer care delivery research trials: the Alliance for Clinical Trials in Oncology experience.
Zahrieh D, Hillman SL, Tan AD, Frank JL, Dockter T, Meyers BJ, Cherevko CL, Peil ES, McCue S, Kour O, Gunn HJ, Neuman HB, Chang GJ, Paskett ED, Mandrekar SJ, Dueck AC. Zahrieh D, et al. Among authors: mandrekar sj. Trials. 2022 Aug 9;23(1):645. doi: 10.1186/s13063-022-06536-x. Trials. 2022. PMID: 35945621 Free PMC article. Review.
CT screening for lung cancer: five-year prospective experience.
Swensen SJ, Jett JR, Hartman TE, Midthun DE, Mandrekar SJ, Hillman SL, Sykes AM, Aughenbaugh GL, Bungum AO, Allen KL. Swensen SJ, et al. Among authors: mandrekar sj. Radiology. 2005 Apr;235(1):259-65. doi: 10.1148/radiol.2351041662. Epub 2005 Feb 4. Radiology. 2005. PMID: 15695622
Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer.
Ma CX, Nair S, Thomas S, Mandrekar SJ, Nikcevich DA, Rowland KM, Fitch TR, Windschitl HE, Hillman SL, Schild SE, Jett JR, Obasaju C, Adjei AA; North Central Cancer Treatment Group; Mayo Clinic; Eli Lilly & Company. Ma CX, et al. Among authors: mandrekar sj. J Clin Oncol. 2005 Sep 1;23(25):5929-37. doi: 10.1200/JCO.2005.13.953. J Clin Oncol. 2005. PMID: 16135464 Clinical Trial.
Future directions in QOL research.
Mandrekar S, Dueck A. Mandrekar S, et al. Curr Probl Cancer. 2005 Nov-Dec;29(6):343-51. doi: 10.1016/j.currproblcancer.2005.09.009. Curr Probl Cancer. 2005. PMID: 16311136 No abstract available.
A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
Ma C, Mandrekar SJ, Alberts SR, Croghan GA, Jatoi A, Reid JM, Hanson LJ, Bruzek L, Tan AD, Pitot HC, Erlichman C, Wright JJ, Adjei AA. Ma C, et al. Among authors: mandrekar sj. Cancer Chemother Pharmacol. 2007 Feb;59(2):207-15. doi: 10.1007/s00280-006-0259-9. Epub 2006 Jun 9. Cancer Chemother Pharmacol. 2007. PMID: 16763792 Clinical Trial.
A limited sample model to predict area under the drug concentration curve for 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomycin.
Furth AF, Mandrekar SJ, Tan AD, Rau A, Felten SJ, Ames MM, Adjei AA, Erlichman C, Reid JM. Furth AF, et al. Among authors: mandrekar sj. Cancer Chemother Pharmacol. 2008 Jan;61(1):39-45. doi: 10.1007/s00280-007-0443-6. Epub 2007 Mar 20. Cancer Chemother Pharmacol. 2008. PMID: 17909811 Clinical Trial.
Endpoints in phase II trials for advanced non-small cell lung cancer.
Mandrekar SJ, Qi Y, Hillman SL, Allen Ziegler KL, Reuter NF, Rowland KM Jr, Kuross SA, Marks RS, Schild SE, Adjei AA. Mandrekar SJ, et al. J Thorac Oncol. 2010 Jan;5(1):3-9. doi: 10.1097/JTO.0b013e3181c0a313. J Thorac Oncol. 2010. PMID: 19884856 Free PMC article.
191 results